Tag: neuromyelitis optica spectrum disorder
Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 ... Read More
AstraZeneca to acquire US biopharma company Alexion Pharmaceuticals for $39bn
AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in ... Read More
US biotech company Viela Bio bags Uplizna FDA approval for NMOSD
Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon) injection for ... Read More